Entrada Therapeutics (TRDA) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Entrada Therapeutics (NASDAQ: TRDA) recently:

• 11/9/2026 – Entrada Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 11/4/2026 – Entrada Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 11/1/2026 – Entrada Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/24/2026 – Entrada Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/19/2026 – Entrada Therapeutics had its “neutral” rating reaffirmed by UBS Group.
• 10/19/2026 – Entrada Therapeutics had its “neutral” rating reaffirmed by HC Wainwright.
• 10/16/2026 – Entrada Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 10/2/2026 – Entrada Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/26/2026 – Entrada Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/16/2026 – Entrada Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Entrada Therapeutics Trading Down 1.5%

Shares of Entrada Therapeutics stock traded down $0.08 on Friday, reaching $5.09. 791,635 shares of the stock were exchanged, compared to its average volume of 345,248. The firm has a market capitalization of $199.27 million, a PE ratio of -1.33 and a beta of -0.19. Entrada Therapeutics, Inc. has a 1-year low of $4.11 and a 1-year high of $16.45. The business has a fifty day moving average price of $5.64 and a two-hundred day moving average price of $8.45.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.01) by $0.07. Entrada Therapeutics had a negative net margin of 4,057.98% and a negative return on equity of 64.00%. The firm had revenue of $0.91 million during the quarter, compared to the consensus estimate of $2.30 million. Research analysts expect that Entrada Therapeutics, Inc. will post -4.16 EPS for the current year.

Insider Transactions at Entrada Therapeutics

In other news, major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $7.54, for a total value of $199,975.88. Following the completion of the transaction, the insider owned 4,332,917 shares in the company, valued at $32,670,194.18. This trade represents a 0.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $7.41, for a total transaction of $1,426,425.00. Following the completion of the sale, the insider owned 3,913,952 shares of the company’s stock, valued at $29,002,384.32. This trade represents a 4.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 495,947 shares of company stock valued at $3,600,470 in the last quarter. Insiders own 9.49% of the company’s stock.

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.